Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of British Columbia
With
Canadian Institutes of Health Research (CIHR)
Canada Foundation for Innovation
Genome Canada
British Columbia Clinical Genomics Network
PURPOSE: To investigate whether genotypic differences can be identified between MS patients who develop liver injury compared to those who do not develop injury in response to beta-interferon therapy.
OBJECTIVE: To determine whether elevated liver enzyme tests (ALT \> 5 times the upper limit of normal) in response to beta-interferon therapy in MS patients is associated with genetic polymorphisms.
METHOD OF RECRUITMENT:
Patients will be identified through a clinic database and chart reviews. An introductory letter will be mailed to potential participants, inviting them to volunteer. A follow-up phone call will be made to determine interest and consent into study.
PROCEDURES:
Saliva will be collected for genetic analyses and a questionnaire will be administered
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
definite MS (Poser or McDonald criteria)
relapsing-remitting or secondary-progressive disease course
Prescribed a beta-interferon as their immunomodulatory drug for MS
You may not be if
primary-progressive MS
an elevated liver test result within 6 months of starting beta-interferon treatment
presence of a co-morbidity that is a known risk-factor for liver injury
